In a sensitivity analysis that excluded the 1 individual with a second malignant neoplasm who harbored a CPV, we found that CPV status in an RMS-associated gene was still significantly associated with outcome, and the outcome estimates did not meaningfully change (<5% change in AHR). Here, AHR is linked to cancer.